• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Synthesis and Biological Evaluation of Quinolinone Compounds as SARS CoV 3CL Inhibitors.喹啉酮类化合物作为SARS冠状病毒3CL蛋白酶抑制剂的合成及生物学评价
Chin J Chem. 2013 Sep;31(9):1199-1206. doi: 10.1002/cjoc.201300392. Epub 2013 Jul 19.
2
Identification of novel 1,2,3-triazole isatin derivatives as potent SARS-CoV-2 3CLpro inhibitors click-chemistry-based rapid screening.新型1,2,3-三唑异吲哚酮衍生物作为强效严重急性呼吸综合征冠状病毒2 3C样蛋白酶抑制剂的鉴定：基于点击化学的快速筛选
RSC Med Chem. 2023 Aug 17;14(10):2068-2078. doi: 10.1039/d3md00306j. eCollection 2023 Oct 18.
3
Identification of Darunavir Derivatives for Inhibition of SARS-CoV-2 3CL.鉴定达芦那韦衍生物对 SARS-CoV-2 3CL 的抑制作用。
Int J Mol Sci. 2022 Dec 16;23(24):16011. doi: 10.3390/ijms232416011.
4
In silico screening-based discovery of novel covalent inhibitors of the SARS-CoV-2 3CL protease.基于计算机筛选发现新型SARS-CoV-2 3CL蛋白酶共价抑制剂
Eur J Med Chem. 2022 Mar 5;231:114130. doi: 10.1016/j.ejmech.2022.114130. Epub 2022 Jan 23.
5
Discovery of naturally occurring inhibitors against SARS-CoV-2 3CL from Ginkgo biloba leaves via large-scale screening.从银杏叶中通过大规模筛选发现针对 SARS-CoV-2 3CL 的天然抑制剂。
Fitoterapia. 2021 Jul;152:104909. doi: 10.1016/j.fitote.2021.104909. Epub 2021 Apr 22.
6
Potential In Vitro Inhibition of Selected Plant Extracts against SARS-CoV-2 Chymotripsin-Like Protease (3CL) Activity.部分植物提取物对新型冠状病毒2型类胰凝乳蛋白酶（3CL）活性的潜在体外抑制作用
Foods. 2021 Jun 29;10(7):1503. doi: 10.3390/foods10071503.
7
Discovery of highly potent covalent SARS-CoV-2 3CL inhibitors bearing 2-sulfoxyl-1,3,4-oxadiazole scaffold for combating COVID-19.发现具有 2-磺酰基-1,3,4-噁二唑骨架的高效共价 SARS-CoV-2 3CL 抑制剂，用于抗击 COVID-19。
Eur J Med Chem. 2023 Nov 15;260:115721. doi: 10.1016/j.ejmech.2023.115721. Epub 2023 Aug 17.
8
Identification of highly effective inhibitors against SARS-CoV-2 main protease: From virtual screening to in vitro study.鉴定针对新型冠状病毒主要蛋白酶的高效抑制剂：从虚拟筛选到体外研究
Front Pharmacol. 2022 Nov 18;13:1036208. doi: 10.3389/fphar.2022.1036208. eCollection 2022.
9
Identifying the natural compound Catechin from tropical mangrove plants as a potential lead candidate against 3CL from SARS-CoV-2: An integrated approach.从热带红树林植物中鉴定出天然化合物儿茶素作为一种针对 SARS-CoV-2 的 3CL 的潜在先导候选物：一种综合方法。
J Biomol Struct Dyn. 2022;40(24):13392-13411. doi: 10.1080/07391102.2021.1988710. Epub 2021 Oct 13.
10
Prioritisation of Compounds for 3CL Inhibitor Development on SARS-CoV-2 Variants.针对 SARS-CoV-2 变异株的 3CL 抑制剂开发进行化合物的优先级排序。
Molecules. 2021 May 18;26(10):3003. doi: 10.3390/molecules26103003.

引用本文的文献

1
Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review.SARS-CoV 和 SARS-CoV-2 主要蛋白酶的结构与功能及其抑制作用：全面综述。
Eur J Med Chem. 2023 Nov 15;260:115772. doi: 10.1016/j.ejmech.2023.115772. Epub 2023 Aug 28.
2
Antimicrobial effects of copper nanoparticles with green tea and neem formulation.绿茶和印楝配方的铜纳米颗粒的抗菌作用
Bioinformation. 2022 Mar 31;18(3):284-288. doi: 10.6026/97320630018284. eCollection 2022.
3
Convenient construction of tetrahydrochromeno[4',3':2,3]indolizino[8,7-]indoles and tetrahydroindolizino[8,7-]indoles one-pot domino reaction.通过一锅法多米诺反应便捷构建四氢色烯并[4',3':2,3]中氮茚并[8,7-]吲哚和四氢中氮茚并[8,7-]吲哚
RSC Adv. 2018 Aug 14;8(50):28736-28744. doi: 10.1039/c8ra05138k. eCollection 2018 Aug 7.
4
Role of heterocyclic compounds in SARS and SARS CoV-2 pandemic.杂环化合物在 SARS 和 SARS-CoV-2 大流行中的作用。
Bioorg Chem. 2020 Nov;104:104315. doi: 10.1016/j.bioorg.2020.104315. Epub 2020 Sep 24.
5
Tubulysin Synthesis Featuring Stereoselective Catalysis and Highly Convergent Multicomponent Assembly.具有立体选择性催化和高聚合度多组分组装的微管蛋白毒素合成。
Org Lett. 2020 Jul 17;22(14):5396-5400. doi: 10.1021/acs.orglett.0c01718. Epub 2020 Jun 25.
6
Reanalysis of Lindenatriene, a Building Block for the Synthesis of Lindenane Oligomers.用于合成土木香烷低聚物的结构单元土木香三烯的再分析
Tetrahedron. 2019 Jun 14;75(24):3140-3144. doi: 10.1016/j.tet.2019.03.011. Epub 2019 Mar 14.
7
Protein-induced low molecular weight hydrogelator self-assembly through a self-sustaining process.蛋白质通过自我维持过程诱导低分子量水凝胶剂自组装。
Chem Sci. 2019 Mar 11;10(18):4761-4766. doi: 10.1039/c9sc00312f. eCollection 2019 May 14.
8
Cross-dehydrogenative coupling for the intermolecular C-O bond formation.交叉脱氢偶联反应在分子间 C-O 键形成中的应用。
Beilstein J Org Chem. 2015 Jan 20;11:92-146. doi: 10.3762/bjoc.11.13. eCollection 2015.

本文引用的文献

1
Synthesis of glutamic acid and glutamine peptides possessing a trifluoromethyl ketone group as SARS-CoV 3CL protease inhibitors.具有三氟甲基酮基团的谷氨酸和谷氨酰胺肽作为严重急性呼吸综合征冠状病毒3CL蛋白酶抑制剂的合成。
Tetrahedron. 2006 Sep 4;62(36):8601-8609. doi: 10.1016/j.tet.2006.06.052. Epub 2006 Jul 14.
2
Inhibitors of SARS-3CLpro: virtual screening, biological evaluation, and molecular dynamics simulation studies.SARS-3CLpro 抑制剂：虚拟筛选、生物评价和分子动力学模拟研究。
J Chem Inf Model. 2011 Jun 27;51(6):1376-92. doi: 10.1021/ci1004916. Epub 2011 May 23.
3
Synthesis and evaluation of pyrazolone compounds as SARS-coronavirus 3C-like protease inhibitors.合成和评价吡唑酮类化合物作为 SARS-冠状病毒 3C 样蛋白酶抑制剂。
Bioorg Med Chem. 2010 Nov 15;18(22):7849-54. doi: 10.1016/j.bmc.2010.09.050. Epub 2010 Sep 25.
4
New developments for the design, synthesis and biological evaluation of potent SARS-CoV 3CL(pro) inhibitors.强效SARS-CoV 3CL（蛋白酶）抑制剂的设计、合成及生物学评价的新进展
Bioorg Med Chem Lett. 2009 May 15;19(10):2722-7. doi: 10.1016/j.bmcl.2009.03.118. Epub 2009 Mar 28.
5
Design, synthesis, and evaluation of trifluoromethyl ketones as inhibitors of SARS-CoV 3CL protease.三氟甲基酮作为严重急性呼吸综合征冠状病毒3CL蛋白酶抑制剂的设计、合成与评估
Bioorg Med Chem. 2008 Apr 15;16(8):4652-60. doi: 10.1016/j.bmc.2008.02.040. Epub 2008 Feb 15.
6
Structure-based design and synthesis of highly potent SARS-CoV 3CL protease inhibitors.基于结构的高效 SARS-CoV 3CL 蛋白酶抑制剂的设计与合成
Chembiochem. 2007 Sep 24;8(14):1654-7. doi: 10.1002/cbic.200700254.
7
A mechanistic view of enzyme inhibition and peptide hydrolysis in the active site of the SARS-CoV 3C-like peptidase.严重急性呼吸综合征冠状病毒3C样蛋白酶活性位点中酶抑制和肽水解的机制性观点。
J Mol Biol. 2007 Aug 24;371(4):1060-74. doi: 10.1016/j.jmb.2007.06.001. Epub 2007 Jun 8.
8
Synthesis, crystal structure, structure-activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor.一种强效严重急性呼吸综合征冠状病毒3CL蛋白酶抑制剂的合成、晶体结构、构效关系及抗病毒活性
J Med Chem. 2006 Aug 10;49(16):4971-80. doi: 10.1021/jm0603926.
9
Isatin compounds as noncovalent SARS coronavirus 3C-like protease inhibitors.异吲哚酮化合物作为非共价SARS冠状病毒3C样蛋白酶抑制剂。
J Med Chem. 2006 Jun 15;49(12):3440-3. doi: 10.1021/jm0602357.
10
The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor.严重急性呼吸综合征病毒主要蛋白酶及其与一种抑制剂复合物的晶体结构。
Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13190-5. doi: 10.1073/pnas.1835675100. Epub 2003 Oct 29.

喹啉酮类化合物作为SARS冠状病毒3CL蛋白酶抑制剂的合成及生物学评价

Synthesis and Biological Evaluation of Quinolinone Compounds as SARS CoV 3CL Inhibitors.

作者信息

Sun Yuanpei, Zhang Ning, Wang Jian, Guo Yu, Sun Bo, Liu Wei, Zhou Honggang, Yang Cheng

机构信息

College of Pharmacy, Nankai University, Tianjin 300071, China.

High Throughput Molecular Drug Discovery Center, Tianjin International Joint Academy of Biotechnology and Medicine, TEDA, Tianjin 300457, China.

出版信息

Chin J Chem. 2013 Sep;31(9):1199-1206. doi: 10.1002/cjoc.201300392. Epub 2013 Jul 19.

DOI:10.1002/cjoc.201300392
PMID:32313409
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7159103/
Abstract

SARS CoV 3CL is known to be a promising target for development of therapeutic agents against the severe acute respiratory syndrome (SARS). A quinolinone compound was selected via virtual screening, and it was synthetized and tested for enzymatic inhibition . Compound showed potent inhibitory activity (IC=0.44 µmol/L) toward SARS CoV 3CL. Further work on a series of quinolinone derivatives resulted in the discovery of the most potent compound , inhibiting SARS CoV 3CL with an IC of 36.86 nmol/L. The structure-activity relationships were also discussed.

摘要

已知严重急性呼吸综合征冠状病毒（SARS-CoV）3CL是开发抗严重急性呼吸综合征（SARS）治疗药物的一个有前景的靶点。通过虚拟筛选选择了一种喹啉酮化合物，并对其进行合成和酶抑制测试。化合物对SARS-CoV 3CL表现出强效抑制活性（IC=0.44 μmol/L）。对一系列喹啉酮衍生物的进一步研究发现了最有效的化合物，其对SARS-CoV 3CL的抑制常数IC为36.86 nmol/L。还讨论了构效关系。